5-[7,7-bis(2-ethylhexyl)-3,11-dithiatricyclo[6.3.0.02,6]undeca-1(8),2(6),4,9-tetraen-4-yl]quinoxaline
C33H42N2S2 — CID 102165521
Data last refreshed: (MolForge compound catalog, from PubChem)
About 5-[7,7-bis(2-ethylhexyl)-3,11-dithiatricyclo[6.3.0.02,6]undeca-1(8),2(6),4,9-tetraen-4-yl]quinoxaline
5-[7,7-bis(2-ethylhexyl)-3,11-dithiatricyclo[6.3.0.02,6]undeca-1(8),2(6),4,9-tetraen-4-yl]quinoxaline (PubChem CID 102165521) has the molecular formula C33H42N2S2 and a molecular weight of 530.85 g/mol. Its IUPAC name is 5-[7,7-bis(2-ethylhexyl)-3,11-dithiatricyclo[6.3.0.02,6]undeca-1(8),2(6),4,9-tetraen-4-yl]quinoxaline.
Molecular Properties
| Compound Name | 5-[7,7-bis(2-ethylhexyl)-3,11-dithiatricyclo[6.3.0.02,6]undeca-1(8),2(6),4,9-tetraen-4-yl]quinoxaline |
|---|---|
| PubChem CID | 102165521 |
| Molecular Formula | C33H42N2S2 |
| Molecular Weight | 530.85 g/mol |
| Exact Mass | 530.28 |
| IUPAC Name | 5-[7,7-bis(2-ethylhexyl)-3,11-dithiatricyclo[6.3.0.02,6]undeca-1(8),2(6),4,9-tetraen-4-yl]quinoxaline |
| SMILES | CCCCC(CC)CC1(CC(CC)CCCC)c2ccsc2-c2sc(-c3cccc4nccnc34)cc21 |
| InChI | InChI=1S/C33H42N2S2/c1-5-9-12-23(7-3)21-33(22-24(8-4)13-10-6-2)26-16-19-36-31(26)32-27(33)20-29(37-32)25-14-11-15-28-30(25)35-18-17-34-28/h11,14-20,23-24H,5-10,12-13,21-22H2,1-4H3 |
| InChIKey | PUKBMCWMUVSZGX-UHFFFAOYSA-N |
| XLogP | 10.90 |
| TPSA | 25.78 Ų |
| H-Bond Donors | |
| H-Bond Acceptors | 4 |
| Rotatable Bonds | 13 |
| Heavy Atoms | 37 |
| Complexity | — |
Lipinski Rule of Five
2 violations
| Rule | Value |
|---|---|
| MW ≤ 500 | 530.85 |
| LogP ≤ 5 | 10.90 |
| H-Bond Donors ≤ 5 | 0 |
| H-Bond Acceptors ≤ 10 | 4 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 102165521 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.